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Introduction
Maladies of the kidneys, such as Chronic Kidney Disease (CKD), Renal Cell Car-cinoma (RCC), and End Stage Renal Dis-
ease (ESRD) have been increasingly recognized in the 
United States as a public health concern and as key 
determinants of poor health outcomes (Garcia-Garcia 
& Jha, 2015; Hofmann & Purdue, 2014; Lipworth et 
al., 2011; Lipworth et al., 2012; McClellan et al., 2006) 
worldwide (Garcia-Garcia & Jha, 2015; Satko et al., 
2007).  Incidents of nephrology differ by race and eth-
nicity.  Various nephrology studies, such as the Reasons 
for Geographic and Racial Differences in Stroke (RE-
GARDS) Cohort Study (2006) and the National Can-
cer Institute (NCI) Surveillance and Epidemiology End 
Results (SEER) Cancer Statistics Review, provide ev-
idence of the disparity that African American patients 
have an increased prevalence of severely impaired 
kidney function compared to Caucasian American   pa-
tients. 
  According to the Mayo Clinic (2017), CKD de-scribes the gradual loss of kidney function.  The kidneys 
filter wastes and excess fluids from the blood, which 
are then excreted in the urine.  When CKD reaches an 
advanced stage, dangerous levels of fluid, electrolytes, 
and wastes can build up in the body and cause further 
damage.  CKD may not become symptomatic until kid-
ney function is significantly impaired.   Treatment fo-
cuses on slowing the progression of the kidney damage, 
usually by controlling the underlying cause.  Gradual 
progression of CKD to end-stage kidney failure is fatal 
without dialysis or a kidney transplant (Mayo Clinic, 
2017).
 Renal disease is a slow-moving, progressive, 
and irreversible condition that is measured in five stag-
es based on the patient’s level of glomerular filtration 
rate (eGFR), the filtering capacity of the kidneys to 
clean the blood, take out waste, and manufacture urine. 
eGFR measures kidney function using a formula that 
includes a person’s age, gender, race, and serum cre-
atinine levels.  Creatinine is a chemical waste mole-
cule generated from muscle metabolism (Hofmann et 
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al., 2013; Hofmann et al., 2015; Mayo Clinic, 2017). 
eGFR under 60 milliliters (mL) may indicate kidney 
disease, while an eGFR of 15-29 requires dialysis or a 
kidney transplant to sustain life.  Inevitably, CKD will 
result in a fatal prognosis of end-stage kidney failure. 
Diabetes and hypertension are two of the most determi-
nant factors of end-stage renal disease (ESRD) in the 
United States, which most often develops during the 
fifth stage, following a CKD diagnosis (Hofmann et al., 
2015; Mayo Clinic, 2017). 
 
 WebMD (2017) outlines how the five stages of 
CKD are determined by eGFR calculation.  Stage 1, 
kidney damage with a normal or high eGFR of 90 or 
above requires monitoring by an urologist.  Diagno-
sis and treatment of comorbid conditions slow disease 
progression and reduce cardiovascular risk.  Stage 2, 
kidney damage with mildly low eGFR of 60-89, an es-
timate of disease progression is determined by an urol-
ogist.  Comorbidities such as diabetes and high blood 
pressure are managed.  Stage 3, kidney damage with 
moderately low eGFR of 30-59, evaluation and treat-
ment of complications such as anemia and bone dis-
ease begin.  Stage 4, kidney damage with severely low 
eGFR of 15-29, signals preparation for treating kidney 
failure, including, kidney replacement therapy.  A ne-
phrologist is consulted.  Stage 5, kidney failure with a 
critically low eGFR of 15 or less requires dialysis, or, 
if the patient chooses, palliative care.  Kidney replace-
ment is the recommended procedure to sustain life, if 
uremia or renal waste is present in the blood (WebMD, 
2017). 
 RCC is the most common type of kidney can-
cer in adults and occurs most often in men, ages 50 to 
70 years old.  The U. S. National Library of Medicine 
(2017) defines RCC as a type of kidney cancer that 
starts in the lining of very small tubes (tubules) in the 
kidney.  The U.S. National Cancer Institute SEER re-
view diagnosed more than 65,000 cancers of the kidney 
and renal pelvis in 2013, with 13,680 estimated deaths. 
New cases in 2017 total 63,990, while projected deaths 
estimate 14,400 (NCI SEER, 2017).  
 Incidents of small renal masses (SRMs) in-
crease approximately 2% per year.  Twenty-five percent 
of SRMs are benign.  Treatment protocols to preserve 
kidney function have produced excellent oncologic 
results for tumor patients.  Generally, elective partial 
nephrectomy (PN) for SRMs is the first-line medical 
approach.  Surgically treated renal tumors less than 4 
centimeters (cm) carry an excellent prognosis, <90% 
of a ten-year, recurrence-free survival rate.  RCC tu-
mors treated surgically exceed the 5-year survival rate 
by 95% in most studies (Blecher & Challancombe, 
2016; Chang, Finelli, Berns, & Rosner, 2014; Shuch, 
Bratslavsky, Linehan, & Srinivasan, 2012; Yap, Finelli, 
Urbach, Tomlinson, & Alibha, 2014).  
 A less invasive, outpatient procedure, percu-
taneous probe ablation or cryotherapy is used to treat 
RCC patients with tumors >3cm.  A surgical syringe 
filled with extremely cold liquid is inserted through the 
skin to freeze and obliterate targeted tumors and ab-
normal cells, while preserving the surrounding tissue. 
Success rates are inferior to PN; nonetheless, consid-
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ered acceptable at <90% recurrence-free rate for some 
populations.  Diagnostic rates of kidney tumor biopsies 
are <80% with a very low complication rate of <5% 
and a benign histology of 25%.  Subsequently, the prac-
tice to biopsy lesions before treatment and repeat the 
process after a non-diagnostic biopsy is 80% success-
ful.  Concordance rates comparing biopsy results and 
surgical pathology approach 100% results for SRMs 
(Blecher & Challancombe, 2016; Chang et al., 2014; 
Yap et al., 2014).   
                 
 ESRD is defined by the U. S. National Library 
of Medicine (2017) as the last stage of chronic kid-
ney disease, when the kidneys can no longer support 
the body’s needs.  ESRD occurs when the kidneys 
malfunction and lose the ability to remove waste and 
excess water from the body.  As a result, the kidneys 
are no longer able to maintain functionality at a level 
needed to sustain life day-to-day.  Diabetes and hyper-
tension are conditions that distress the kidneys and are 
two of the most common determinant factors of ESRD 
in the United States.  ESRD predominantly develops 
after CKD.  Cessation of kidney function happens over 
a course of 10 to 20 years before end-stage disease re-
sults (NLM NIH, 2017).
Epidemiology of CKD Disparity
 The research of Garcia-Garcia and Jha (2015) 
explores how poverty negatively influences healthy be-
haviors, limits healthcare access, and minimizes envi-
ronmental exposure to health information.  The poor 
are more susceptible to disease due to high-risk com-
munity environments and social disadvantages, such 
as the lack of access to goods and services, minimal 
exposure to clean water and sanitation, insufficient nu-
trition, and limited information about prevention and 
safety.   Roadblocks to accessing adequate healthcare 
impede urban and rural impoverished communities and 
embody a shortage of regional medical facilities, few-
er doctors and specialists, and lack of accessible trans-
portation.  Although the United States is a prominent-
ly developed country, the poor and ethnic minorities, 
predominantly African Americans, suffer from higher 
incidents of ESRD (Garcia-Garcia & Jha, 2015). 
       
 Data from the REGARDS Cohort Study reveal 
that in the United States, ethnic minorities most prev-
alently, African Americans, have the highest incident 
rates of ESRD.  The racial disparity gap was 3.8, in 
contrast to Caucasian American patients, who, in 2000, 
accounted for 64% of the ESRD incident population 
and 77% of the overall U.S. population of ESRD cases. 
Age-adjusted ESRD rates in 2000 indicate 982 people 
per million among African Americans and 256 people 
per million among Caucasian American individuals 
with the disease (McClellen et al., 2006). 
  
 Correlation between low birth weight (LBW) 
and CKD, due to nutritional factors and kidney disease, 
has been described as notable in poor African Ameri-
cans and Caucasian Americans living in southeastern 
regions of the USA, such as Tennessee, North Caroli-
na, Kentucky, Mississippi, Georgia, and the like.  Sim-
ilarly, findings revealed a southeast Native cohort with 
LBW and early malnutrition was associated with later 
development of metabolic syndrome, diabetes, and di-
Bridgewater State University94  The Graduate Review 2018     
abetic nephropathy.  A high prevalence of proteinuria, 
elevated blood pressure, and CKD of unknown etiology 
was discovered (Garcia-Garcia & Jha, 2015). 
  
 Lipworth and colleagues (2012) report that the 
disparity gap between Caucasian and African Americans 
affected by CKD continues to grow.  Still, the causal 
circumstance responsible for the increasing prevalence 
of severely impaired kidney function among African 
American patients remains undetermined.  Consistent 
factors associated with increased renal cell cancer risk 
in epidemiologic studies are obesity, hypertension, and 
cigarette smoking and account for less than half of can-
cers among Caucasian Americans.  Due to enigmatic 
differences in incidence and mortality trends, African 
Americans are represented as the population at the 
highest risk (Lipworth et al., 2012).
 Risk factors for ESRD are categorized by low 
income males with an annual salary below $15,000.00 
per year; minimal education; smoking; a history of di-
abetes and hypertension; and a history of myocardial 
infarction (MI/CABG), obesity, and high cholesterol. 
The risk of developing ESRD among African Ameri-
cans vs. Caucasian Americans decreases after adjust-
ments are made to the factors (Lipworth et al., 2012). 
 
 Cancer in itself is a complex topic; wherefore, 
a striking pattern of racial differences exists for CKD. 
An observed disparity in ESRD incidence between Af-
rican Americans and Caucasian Americans may have 
occurred, in part, due to racial differences in the rate 
of progression of CDK to ESRD.  In a San Francisco 
Community Health Network population study, African 
Americans with stages 3 to 5 had a four-fold higher risk 
of progression to ESRD than Caucasian Americans af-
ter adjustment for socioeconomic status.  Early stage 
CKD is deemed higher among Caucasian Americans 
compared with African Americans.  This analysis is 
based on eGFR, the glomerular filtration rate, or how 
fast the kidneys are filtering blood and removing excess 
wastes and fluids.  Results show the Caucasian Amer-
ican excess for mild CKD gives way to an excess for 
moderate to severe CKD in African Americans (Lip-
worth et al., 2012).  
 Perhaps, pattern changes in the progression of 
CKD may be due to lower mortality at higher eGFR 
levels among African Americans.  Nonetheless, empiri-
cal evidence demonstrates death rates of African Amer-
icans are higher at all levels of CKD prior to ESRD. 
Rates of ESRD incidence are five times higher than 
rates of cardiovascular deaths among African Amer-
icans with hypertension.  African Americans remain 
at risk for faster transitions to moderate and advanced 
CKD and eventually ESRD (Lipworth et al., 2012).          
Access to Medical Treatment
 The populations discussed in this paper ac-
cessed healthcare primarily from local community 
healthcare clinics and facilities and hospital emergency 
rooms.  There were some populations in the Hoffman 
and Purdue (2014) study whose records were surveyed 
through the Kaiser Permanente Northern California 
system.  The author of one of the articles contributed a 
note indicating that data collection did not assume that 
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some of the minority participants may have had a job 
with appropriate medical benefits.  The benefits were 
determined by the access to testing and other care pro-
visions and access to care data (Hofmann & Purdue, 
2014). 
 
 Other global populations presented by members 
of the World Kidney Day Steering Committee, as in-
dicated by Garcia-Garcia & Jha (2015), discussed the 
key links between poverty and CKD as consequent im-
plications for the prevention of kidney disease and the 
care of kidney patients in various populations.  Com-
pelling evidence shows disadvantaged societies, those 
from low-resource, racial and minority, ethnic commu-
nities, and indigenous and socially disadvantaged back-
grounds, suffer from marked increases in the burden of 
unrecognized and untreated CKD.  The same inequity 
holds true in the United States (Garcia-Garcia & Jha, 
2015).      
  
 ESRD is the only disease protected by a Medi-
care mandate and a series of Amendments: (P.L. 92-
603) under the Social Security Act passed by the Unit-
ed States Congress in 1972, 1978; (P.L. 95-292) 1981; 
(P.L. 97-35) 2003; (P.L. 108-173) 2008; (P.L. 110-275) 
2012; ATRA, P.L. 112-240).  ESRD requires lifelong 
dialysis treatment.  More commonly, nephrologists pre-
fer to offer patients self-administered home treatment 
options such as hemodyalisis, a catheter system that is 
injected primarily in the arm in a localized vein source 
or inserted in a stint installed in the arm.  Peritoneal is a 
catheter implanted in the abdomen wall.  Service is per-
formed daily via machine and provides a 40% decrease 
in mortality risk (CSM, 2012: Gehlert & Brown, 2012). 
 A  kidney transplant has proven to be the most 
expensive yet more viably permanent solution to combat 
CKD; however, according to Gehlert & Brown (2012), 
Caucasian American males are more likely recipients of 
a kidney transplant than any other demographic group 
in the United States.  African American ESRD patients 
are much less likely to be referred, placed on a waiting 
list, or receive a kidney transplant.  The extent of the 
disparity points to the limited number of African Amer-
ican patients who willingly participate in preventative 
care, harbor distrust for the medical community, and 
lack informed knowledge about kidney transplanta-
tion and general, medical eligibility (Gehlert & Brown, 
2012).  
 Recipients are required to partake in an exten-
sive evaluation and be placed on a waiting list if they 
are unable to identify a living donor.  A “paired” do-
nor, or altruistic donor sourced from a support network 
such as United Network of Organ Sharing, Georgetown 
University Hospital, may be appropriate.  Transplant 
recipients take immune-suppressants for the life of the 
kidney to avoid body rejection.  If the plan fails, the 
patient returns to dialysis (Gehlert & Brown, 2012).        
Healthy People 2020
 Healthy People 2020 is a federally mandated ob-
jective funded in support by an annual block grant pro-
gram, administered by the U. S. Department of Health 
and Human Services.  One of the objectives of Healthy 
People 2020 is to increase the number of persons who 
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receive kidney transplants (Gehlert & Brown, 2012). 
Not all patients are medically suitable for transplant 
surgery due to comorbid health complications such as 
cardiovascular disease or psychosocial stress resulting 
from obesity.  Patients self-determine treatment prefer-
ences (Gehlert & Brown, 2012).         
National ESRD Program (NESRD) – Public Law 
(92-603)
 The national ESRD law passed on October 30, 
1972, after significant lobbying by patients, their fam-
ilies, and communities, in response to the rationing of 
dialysis care.  Public Law (92-603) provides coverage 
of dialysis or kidney transplantation for all ESRD pa-
tients through Medicare, regardless of age, and pays 
expenses for kidney donors and paired donors.  ESDR 
is the only disease category to guarantee eligibility 
through Medicare, provided the patient or spouse/par-
ent/guardian can prove sufficient work history (CSM, 
2012; Gehlert & Brown, 2012).    
Demographics
 Sixty-five plus is the fastest growing popula-
tion age of ESRD patients.  Patients present with more 
co-morbidities as they age, such as diabetes, hyper-
tension, RCC, renal cancer, CKD, more psychosocial 
issues, and physical problems.  Kidney disease dis-
proportionately affects African Americans, Hispanics, 
Native Americans, and Alaskan Natives.  Minorities 
and homeland native recipients are more likely to de-
velop renal failure compared to Caucasian Americans 
with ESRD incidence.  Caucasian Americans usually 
die of cardiovascular disease before reaching a level 
of mature ESRD incidence (Gehlert & Brown, 2012; 
Tarver-Carr et al., 2012; Yap et al., 2014).  
 Two hundred, seventy-three per million Cauca-
sian Americans vs. nine hundred, ninety-eight African 
Americans per million; five hundred, eight per million 
Hispanics; four hundred, ninety-five per million Native 
Americans; and two hundred, ninety-six per million 
Asians develop renal disease (Data collected from U.S. 
Renal Data, 2009).  There is a greater prevalence of di-
abetes and hypertension in minority populations.  Six-
ty percent of dialysis patients experience chronic pain. 
Sixty-six percent use prescription pain medication (Ge-
hlert & Brown, 2012; Mafolasire et al., 2016). 
 Comparatively, Caucasian American males 
with kidney disparity are more likely to receive trans-
plants than any other demographic in the U.S., while 
African Americans are much less likely to be referred 
for transplants and are more often placed on a waiting 
list.  Potential reasons are an identified lack of preventa-
tive care, patient preference, socioeconomic status, dis-
trust of the medical community, and lack of knowledge 
about transplantation and related medical conditions. 
(Gehlert & Brown, 2012; Mafolasire et al., 2016). 
 The National Cancer Institute SEER program 
reports approximately 1.6% of men and women will be 
diagnosed with kidney and renal pelvis cancer in their 
lifetime.  In 2014, there were an estimated 483,225 peo-
ple in the United States living with kidney and renal 
pelvis cancer.  The number of new cases was estimat-
ed at 15.6 per 100,000 men and women per year, with 
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deaths estimated at 3.9 per 100,000 men and women 
per year.  The percentage of patients surviving 5-years 
in 2014 was 74.1% (2017). 
 Cancer survival is estimated by stage at diag-
nosis.  Stage refers to the extent of cancer in the body 
and determines treatment options.  Abnormal cancer 
cells found in the part of the body where it started is 
referred to as localized or Stage 1.  As cancer metas-
tasizes, the stage is referred to as regional or distant. 
Kidney and renal pelvis cancers are diagnosed at the 
local stage 65.2% of the time.  The 5-year survival rate 
for localized kidney and renal pelvis cancer is 92.6% 
(NCI SEER, 2017).     
Emphasis on Poverty
 Many studies demonstrate the bidirectional re-
lationship between poverty and chronic kidney disease. 
Patients lacking financial means or adequate insurance 
coverage become vulnerable and are often burdened 
with meeting huge, out-of-pocket costs to cover ESRD 
treatment.  The financial strain associated with kidney 
disease progression impacts patients and their families 
in ways that can thrust them into circumstances of ex-
treme poverty (Garcia-Garcia & Jha, 2015).   
 Overall, the poor carry a higher disease burden 
and limited access to resources for meeting treatment 
costs.  Neighborhood poverty is strongly associated 
with higher ESRD incidents for both African Ameri-
cans and Caucasians.  Despite the persistent disparity 
of ESRD across all poverty levels, greater risk exists 
for African Americans.  Subsequently, the possibility 
exists that African Americans suffer more from lower 
socioeconomic status than Caucasians (Volkaova et al., 
2008).            
Palliative Care/End of Life Issues
 End of life issues and palliative care options are 
prevalent with ESRD.  The life expectancy is 75% low-
er than similar patients with chronic, life-threatening 
conditions other than ESRD.  Ceasing treatment leads 
to death.  Ninety-six percent of the patients who stop 
dialysis treatment are deceased within a month (Gehlert 
& Brown, 2012).  
    
 Sixty percent of patients change their careers or 
apply for supplemental security income or Social Se-
curity Disability insurance (SSI or SSDI) due to ESRD 
treatment.  The disease health maintenance process 
takes an emotional and financial toll on individuals and 
families to a level that can potentially leave them desti-
tute (Gehlert & Brown, 2012).  
  
 Patients are recommended to follow a strict diet. 
Processed foods are not condoned.  Foods with high po-
tassium levels lead to heart failure.  High phosphorous 
foods lead to bone disease and calcification of the heart. 
Kidney patient diets are tough to follow and difficult to 
uphold (Gehlert & Brown, 2012).                
Challenges for Social Workers
 As chronic renal disease slowly progresses to 
ESRD, clients face significant socio-emotional and 
lifestyle changes.  The intrusiveness of the treatment 
causes multiple disease-related and treatment-related 
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psychological stressors.  Clients are faced with a bleak 
prognosis of planning how long they can expect to live 
on dialysis, and how treatment will impact their qual-
ity of life and that of their families (Gehlert & Brown, 
2012).   
 Many ESRD patients struggle with psychoso-
cial issues and harbor legitimate, personal concerns. 
Clients are often coping with debilitating physical pain 
prior to their death.  There are significant psychosocial 
ramifications for families adjusting and coping with the 
impact and life-changing finality of the disease.  The 
significance of the psychosocial issues faced by clients 
and their families requires culturally competent, com-
passionate, and specialized intervention (Gehlert & 
Brown, 2012).            
 Typically, ESRD patients are referred to a hos-
pital social worker, specializing in nephrology or renal 
social work.  ESRD is the only disease category with 
a public policy mandate under Medicare, stipulating a 
Master’s Degree-level social work clinician on health 
teams.  Every dialysis facility and kidney transplant 
program is required to have a Master’s Degree- level 
social worker on staff (Gehlert & Brown, 2012).  
 The integral purpose of a hospital social worker 
is to develop a flexible treatment plan, in collaboration 
with the client and the treatment team.  Options should 
include coping mechanisms, talk therapy (Dialectic 
Behavior Therapy [DBT]), cognitive support (Cogni-
tive Behavior Therapy [CBT]), writing therapy, and a 
safe and comfortable environment for the client to be 
able to release and shed some of the pain and grief from 
the losses incurred as the disease transitions.  Social 
workers are advised to be prepared by having a crisis 
intervention plan at the ready and a Plan B (Gehlert & 
Brown, 2012).   
             
 Each ESRD patient is unique and can present 
with various symptoms, such as impaired sense of 
taste, diminished appetite, and bone disease.  Toxins 
build up in the blood, causing pain, anemic and ure-
mic episodes, and can lead to symptoms of confusion, 
lethargy, sleep problems, and residual psychosocial ef-
fects.  Energy becomes diminished as nutritional sta-
tus is compromised (Cuppari & Ikizler, 2010; Gehlert 
& Brown, 2012).  Overall quality of life is hindered. 
Complex medications may be prescribed to counteract 
symptoms.  Reactions to medications are common until 
the patient’s body adjusts to the dramatic life changes. 
Palliative care is also inevitable.  Kidney disease takes 
a toll on the entire family and requires that all natural 
supports are available to help the patient navigate liv-
ing with disease (Cuppari & Ikizler, 2010; Gehlert & 
Brown, 2012). 
Interventions
 Psychosocial issues faced by ESRD patients 
and their families are significant.  Training as a nephrol-
ogy social worker would be required to understand the 
intricate and complex needs and the specialized cir-
cumstances that challenge clients.  Knowledge of pub-
lic policy would be effective if planning to advocate 
for legislation to support kidney care issues and to help 
lower adjunct medical and prescription costs.  We live 
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in transitional times.  The only thing we can depend 
on is change; therefore, staying current on issues and 
trends in the field reflect a commitment to professional 
responsibility.     
 One of the most effective ways social workers 
can support their clients is by connecting them with ac-
cessible and available resources, including Medicare, 
Medicaid, housing, support groups, medical equipment, 
day-treatment facilities, and specialized programming. 
Helping our clients to master themselves and build con-
fidence toward partnership with others is a monumental 
and honorable task.  
 In conclusion, in order to best serve our clients, 
we as social workers, must first be willing to challenge 
ourselves in a manner that honors the National Associ-
ation of Social Workers (NASW) code of ethics.  We 
have a fundamental duty to place the client’s needs first. 
Being authentic with our clients requires a durability 
that depends on our commitment to mastering and ac-
cepting our own values as social workers.       
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